This is not a paradox. It is merely inconvenient.
Moderna and Merck say their experimental personalized mRNA therapy, intismeran autogene, met two endpoints in a Phase 3 melanoma trial. The therapy was given with pembrolizumab, sold as Keytruda, after patients had their cancer surgically removed.
The INTerpath-001 trial enrolled 1,137 people. TIME described them as having stage 2 through stage 4 melanoma. Participants were assigned two-to-one to receive the combination or Keytruda alone for roughly a year.
The companies reported success on recurrence-free survival. BioSpace reported that the trial also met its secondary endpoint involving survival without distant metastasis.
That is the encouraging part. Meeting Phase 3 endpoints is not nothing.
Now comes the inconvenience.
The companies did not disclose the effect sizes or specific recurrence and survival rates. Detailed safety results were also withheld. BioSpace reported only the companies’ summary that safety was consistent with earlier studies and that no new signals appeared.
Overall survival is still being assessed. More detailed results are supposed to come later.
We have the verb—met—but not the yardstick.
How large was the difference? What was the full adverse-event picture? Did participants live longer?
The announcement does not yet answer those questions.
Moderna CEO Stephane Bancel described the intended mechanism this way: “This product basically allows us to teach the immune system about the mutation in your cancer that allows the cancer to grow.”
That explains the idea. It does not supply the missing measurements.
The stock market supplied a measurement of its own. BioSpace reported that Moderna shares rose 91 percent, reaching $120 in premarket trading after the announcement. RBC Capital Markets analysts called the early news “a surprisingly positive development,” while William Blair analysts called it “a clear positive for shares and Moderna’s fundamental business.”
Those are judgments about timing, expectations and shares. They are not clinical outcomes.
Intismeran remains investigational and is not approved. Moderna and Merck plan to discuss possible approval filings with regulators. BioSpace reported that the FDA had previously discouraged an approval effort based on the Phase 2 results.
A planned discussion is not an approval. The available reports give no date when patients might receive the therapy outside a study.
The honest account is therefore longer than the exciting one.
The trial met two endpoints. The size of the benefit has not been disclosed. Detailed safety data remain unavailable. Overall survival follow-up continues. Regulators have not decided.
That is not bad news.
It is unfinished news.
The stock got its number. Patients still deserve theirs.